You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 8,563,698

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,563,698

Title:	Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
Abstract:	Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
Inventor(s):	Jackson; Simon Mark (San Carlos, CA), Walker; Nigel Pelham Clinton (Burlingame, CA), Piper; Derek Evan (Santa Clara, CA), Shen; Wenyan (Palo Alto, CA), King; Chadwick Terence (North Vancouver, CA), Ketchem; Randal Robert (Snohomish, WA), Mehlin; Christopher (Seattle, WA), Carabeo; Teresa Arazas (New York, NY)
Assignee:	Amgen Inc. (Thousand Oaks, CA)
Application Number:	12/474,176
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,563,698
Patent Claims:	1. An isolated monoclonal antibody, wherein, when bound to PCSK9, said monoclonal antibody binds to at least one residue within the sequence set forth by residues 123-132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding between PCSK9 and an EGFa domain of LDLR protein antagonizes PCSK9's inhibition of cellular LDL uptake. 2. The isolated monoclonal antibody of claim 1, wherein the monoclonal antibody comprises a humanized or human antibody. 3. The isolated monoclonal antibody of claim 1, wherein the monoclonal antibody comprises a full length monoclonal antibody. 4. The isolated monoclonal antibody of claim 3, wherein said monoclonal antibody is of the IgG4- or the IgG2-type. 5. A pharmaceutical composition comprising the monoclonal antibody of claim 1. 6. The isolated monoclonal antibody of claim 1, wherein the monoclonal antibody is an immunologically functional fragment.

Details for Patent 8,563,698

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen, Inc.	REPATHA	evolocumab	Injection	125522	08/27/2015	⤷ Try a Trial	2027-08-23
Amgen, Inc.	REPATHA	evolocumab	Injection	125522	07/08/2016	⤷ Try a Trial	2027-08-23
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 8,563,698

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration
Argentina	068011	⤷ Try a Trial
Argentina	110799	⤷ Try a Trial
Australia	2008288791	⤷ Try a Trial
Australia	2013203677	⤷ Try a Trial
Australia	2013203685	⤷ Try a Trial
Australia	2013203689	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.